Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 2018

View Archived Issues

Acrizanib shows efficacy as topical ocular therapy in models of choroidal neovascularization

Patient enrollment ongoing in phase I trial of HA-1 T TCR T-cell Immunotherapy

Samsung Bioepis initiates phase III trial of proposed ranibizumab biosimilar, SB-11

ST-002 is granted FDA orphan drug designation

Terns Pharmaceuticals acquires three therapeutic candidates for the treatment of NASH from Lilly

AmnioStem cells show superior immune modulatory ability compared to other stem cell types

MCM7 found as a useful marker for intestinal NET grading

Tie1 is a biomarker of survival in patients with metastatic breast cancer

Karo Pharma resolves rights issue regarding acquisition of product portfolio from LEO Pharma

Ubiquigent, FORMA Therapeutics enter DUB enzyme inhibitor collaboration

Biogen and Samsung Bioepis cleared to commercialize Imraldi following AbbVie settlement

Sorrento Therapeutics and Celularity start screening for CD38 CAR-T therapy phase I trial

Ferring Pharmaceuticals to acquire Rebiotix

Strategic collaboration agreement between Nektar and Bristol-Myers Squibb becomes effective

Takeda and DNDi collaborate to develop potential novel drug for visceral leishmaniasis

Injectable hydrogel releases corticosteroid in response to arthritis flares

First cohort dosed in phase I clinical study of PB-2452

Vaccibody initiates first-in-human trial of neoantigen cancer vaccine

SOX-9 successfully distinguishes hepatocellular carcinoma from cholangiocarcinoma

Biopharma Works patents novel serine racemase inhibitors

Menin/MLL interaction inhibitors disclosed by Vitae Pharmaceuticals

Arbutus Biopharma identifies new HBV capsid inhibitors

Aurigene Discovery Technologies divulges new PD-1 inhibitors

Genoscience Pharma initiates first-in-human study of GNS-561 in advanced hepatocellular carcinoma

Decreased OXTR gene methylation tied to schizophrenia

European Commission grants marketing authorization to Lamzede

New phase IIb study explores use of sepranolone for premenstrual dysphoric disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...